Brokerages expect Aethlon Medical, Inc. (NASDAQ:AEMD) to post earnings of -$0.12 per share


Stock analysts expect Aethlon Medical, Inc. (NASDAQ: AEMDGet a rating) will report earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Two analysts provided earnings estimates for Aethlon Medical. The lowest EPS estimate is ($0.16) and the highest is ($0.08). Aethlon Medical reported earnings of ($0.15) per share in the same quarter last year, which would indicate a positive growth rate of 20% year over year. The company is due to announce its next results on Monday, January 1.

On average, analysts expect Aethlon Medical to report annual earnings of ($0.58) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0. $.54). For the next fiscal year, analysts expect the company to post earnings of $2.46 per share. Zacks EPS calculations are an average based on a survey of sell-side analysts who provide coverage for Aethlon Medical.

Aethlon Medical (NASDAQ: AEMDGet a rating) last released its quarterly results on Monday, February 14. The medical equipment supplier reported ($0.16) earnings per share for the quarter, missing Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). The company posted revenue of $0.02 million in the quarter, versus analyst estimates of $0.26 million. Aethlon Medical had a negative net margin of 2,823.49% and a negative return on equity of 45.91%. In the same quarter last year, the company achieved EPS of ($0.20).

Several brokerages have recently commented on the AEMD. StockNews.com began covering shares of Aethlon Medical in a report on Wednesday, April 27. They set a “sell” rating for the company. Maxim Group cut its price target on Aethlon Medical shares from $11.00 to $4.00 in a Tuesday, February 15 report.

Institutional investors and hedge funds have recently changed their holdings in the company. BlackRock Inc. increased its position in Aethlon Medical by 771.7% during the third quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment supplier worth $282,000 after acquiring an additional 64,691 shares during the period. Geode Capital Management LLC increased its position in Aethlon Medical by 32.3% during the third quarter. Geode Capital Management LLC now owns 136,451 shares of the medical equipment supplier worth $526,000 after acquiring an additional 33,330 shares during the period. Renaissance Technologies LLC bought a new position in Aethlon Medical during the third quarter worth approximately $196,000. Dimensional Fund Advisors LP bought a new position in Aethlon Medical during the third quarter for a value of approximately $397,000. Finally, Jane Street Group LLC bought a new position in Aethlon Medical during the third quarter worth approximately $101,000. 10.58% of the shares are currently held by institutional investors.

Shares of DMAE opened at $1.07 on Monday. Aethlon Medical has a 12-month low of $1.07 and a 12-month high of $12.49. The company has a fifty-day simple moving average of $1.31 and a 200-day simple moving average of $1.93. The stock has a market capitalization of $16.49 million, a price-earnings ratio of -1.78 and a beta of 0.65.

Aethlon Medical Company Profile (Get a rating)

Aethlon Medical, Inc, a medical technology company, is focused on developing products to diagnose and treat life-threatening and organ-threatening diseases in the United States. The Company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

See also

Get a Free Copy of Zacks’ Research Report on Aethlon Medical (AEMD)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com



Get news and reviews for Aethlon Medical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Aethlon Medical and related companies with MarketBeat.com’s free daily email newsletter.

Comments are closed.